SCHEDULE: Armistice Capital Discloses 4.99% Stake in Helius Medical

Armistice Capital and Steven Boyd reported a 4.99% beneficial ownership stake in Helius Medical Technologies, Inc. Class A Common Stock.

Summary

• Armistice Capital, LLC and Steven Boyd collectively reported beneficial ownership of 180,028 shares of Helius Medical Technologies, Inc. Class A Common Stock.
• This ownership represents 4.99% of the Class A Common Stock outstanding.
• The shares are held by Armistice Capital Master Fund Ltd., an investment advisory client of Armistice Capital, LLC.
• Armistice Capital, LLC, as the investment manager, and Steven Boyd, as its managing member, exercise shared voting and dispositive power over these shares.
• The filing is an Amendment No. 1 to a Schedule 13G, indicating an update to a previously reported beneficial ownership position.

Sentiment

Score: 6

Explanation: The filing indicates a significant, though passive, institutional investment in Helius Medical Technologies, suggesting a degree of confidence from Armistice Capital, which is generally a neutral to slightly positive signal.

Positives

• The disclosure of a significant stake (4.99%) by an institutional investor like Armistice Capital, LLC, may signal confidence in Helius Medical Technologies, Inc.

Negatives

• The filing itself does not contain negative information regarding the company's performance or outlook.

Risks

• The Master Fund, as the direct holder of the shares, disclaims beneficial ownership due to its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital, which is a standard arrangement but highlights the delegation of control.

Future Outlook

No forward-looking statements or guidance were provided in this beneficial ownership filing.

Industry Context

This filing indicates an institutional investment in Helius Medical Technologies, Inc., a company operating in the medical technology sector. Such investments reflect investor interest in the sector's potential and specific company prospects.

Related Party Transactions

• Armistice Capital, LLC serves as the investment manager for Armistice Capital Master Fund Ltd., which is the direct holder of the shares. Steven Boyd is the managing member of Armistice Capital, LLC. This structure defines the relationship between the reporting persons and the entity holding the shares.

Stakeholder Impact

• Shareholders may view the disclosure of a significant institutional stake as a positive indicator of investor interest and potential validation of the company's value.

Key Dates

Keywords

Helius Medical Technologies, Armistice Capital, Steven Boyd, Beneficial Ownership, Schedule 13G, Class A Common Stock, Medical Technology, Investment Management